Moderna Inc. (NASDAQ:MRNA) stock is trading lower after it rallied around 170% on Wednesday on upbeat data from individualized cancer therapy for advanced skin cancer.
At a pre-planned interim analysis, Merck & Co Inc. (NYSE:MRK) and Moderna’s investigational combination delivered statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival compared to standard Keytruda alone.
Analyst Upgrades Moderna On Intismeran Outlook
On Wednesday, William Blair upgraded Moderna from Market Perform to Outperform.
Analyst Myles Minter adjusted the financial model for Moderna to reflect an increased probability of success for intismeran’s approval in adjuvant melanoma (raised from 65% to 90%).
